PFE Latest Press Releases

-- July 22, 2026 --

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer Business Wire 4:30 PM

-- July 15, 2026 --

AM Best Affirms Credit Ratings of Blue Whale Re Ltd. Business Wire 10:04 AM

-- July 10, 2026 --

U.S. FDA Approves PADCEV plus Keytruda as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility Business Wire 11:23 AM

-- June 24, 2026 --

Pfizer Declares Third-Quarter 2026 Dividend Business Wire 3:52 PM

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance Business Wire 2:10 PM

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market Globe Newswire 8:30 AM

-- June 23, 2026 --

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts Business Wire 10:00 AM

-- June 22, 2026 --

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Business Wire 4:30 PM

-- June 18, 2026 --

Pfizer Announces Chief Financial Officer Transition Business Wire 6:45 AM

-- June 9, 2026 --

Cancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation Accelerates Globe Newswire 9:44 AM

-- June 8, 2026 --

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need Business Wire 6:45 AM

-- June 6, 2026 --

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide Business Wire 9:00 AM

-- June 1, 2026 --

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire 10:00 AM

Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode Globe Newswire 9:05 AM

-- May 31, 2026 --

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer Business Wire 8:00 AM

-- May 30, 2026 --

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer Business Wire 8:00 AM

-- May 29, 2026 --

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer Business Wire 8:00 AM

-- May 28, 2026 --

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines PRNewswire 7:00 PM

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines Business Wire 7:00 PM

-- May 27, 2026 --

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire 10:00 AM

-- May 20, 2026 --

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results Business Wire 5:05 AM

-- May 18, 2026 --

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 PRNewswire 8:00 AM

-- May 13, 2026 --

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors Business Wire 6:45 AM

-- May 12, 2026 --

Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates Globe Newswire 9:00 AM

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant) Globe Newswire 7:00 AM

-- May 11, 2026 --

The Next Generation of the GLP-1 Revolution Is Already Underway Globe Newswire 8:30 AM

-- May 5, 2026 --

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance Business Wire 6:45 AM

-- May 1, 2026 --

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer Globe Newswire 12:43 PM

-- April 29, 2026 --

Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma Business Wire 6:45 AM

-- April 28, 2026 --

Pfizer Reaches Three Settlement Agreements for VYNDAMAX Business Wire 10:17 AM

-- April 24, 2026 --

Bristol Myers Squibb and Pfizer to Make Eliquis (apixaban) Available via Mark Cuban Cost Plus Drug Company Business Wire 6:59 AM

-- April 22, 2026 --

Pfizer Declares Second-Quarter 2026 Dividend Business Wire 4:45 PM

-- April 21, 2026 --

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026 Business Wire 11:51 AM

-- April 20, 2026 --

U.S. FDA Grants Priority Review to sBLA for PADCEV + Keytruda as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility PRNewswire 6:45 AM

-- April 9, 2026 --

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders Business Wire 10:00 AM

-- April 8, 2026 --

Telix Strengthens Board with Additional Director Appointments Globe Newswire 6:44 PM

-- April 7, 2026 --

AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities Globe Newswire 8:30 AM

-- March 24, 2026 --

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts Business Wire 10:00 AM

-- March 23, 2026 --

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial Business Wire 6:45 AM

-- March 20, 2026 --

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC Business Wire 4:30 PM

-- March 19, 2026 --

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer Business Wire 6:45 AM

-- March 17, 2026 --

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer Business Wire 6:45 AM

-- March 9, 2026 --

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis Business Wire 6:45 AM

-- March 4, 2026 --

ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP Globe Newswire 8:32 AM

-- March 2, 2026 --

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM

-- February 27, 2026 --

PADCEV + Keytruda Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer Business Wire 10:00 AM

-- February 25, 2026 --

ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen Business Wire 2:00 PM

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing Business Wire 2:00 PM